Pure Global

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures - Trial NCT06405464

Access comprehensive clinical trial information for NCT06405464 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Zurich and is currently Recruiting. The study focuses on HIV Infections. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06405464
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06405464
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting

Study Focus

HIV Infections

VOCABRIA 30Mg Tablet

Observational

drug

Sponsor & Location

University of Zurich

Zurich, Switzerland

Timeline & Enrollment

N/A

Mar 01, 2022

Jun 30, 2026

600 participants

Primary Outcome

Proportion of individuals with viral blips,Proportion of individuals with confirmed viral failures,Proportion of individuals switching off CAB+RPV LA to previous or another oral regimen,Time to viral failure,Proportion of participants who discontinue treatment due to drug-related reasons,Proportion of participants who discontinue treatment due to drug-unrelated reasons,Proportion of participants by characteristics,Overall adherence to Swiss label indication in CAB+RPV LA prescriptions,Overall adherence to the proposed injection schedules,Proportion of participants by treatment adherence category

Summary

This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA
 regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this
 large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess
 virological, immunological, demographic, clinical, and behavioural factors associated with
 viral failure under CAB+RPV LA regimen.

ICD-10 Classifications

HIV disease resulting in other viral infections
HIV disease resulting in other bacterial infections
HIV disease resulting in multiple infections
Acute HIV infection syndrome
HIV disease resulting in other infectious and parasitic diseases

Data Source

ClinicalTrials.gov

NCT06405464

Non-Device Trial